Volume 124, Issue 1 , Pages 45-51.e4, July 2009
Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction
Background
The patterns of airway remodeling and the biomarkers that distinguish different subtypes of severe asthma are unknown.
Objectives
We sought to characterize subjects with severe asthma with and without chronic persistent airflow obstruction with respect to airway wall remodeling (histopathologic and radiologic) and specific sputum biomarkers.
Methods
Subjects with severe asthma with chronic persistent (n = 16) or intermittent (n = 18) obstruction were studied. Endobronchial biopsy specimens were analyzed for airway smooth muscle area, epithelial detachment, basement membrane thickness, and submucosal fibrosis. Levels of eosinophil cationic protein, myeloperoxidase, matrix metalloproteinase 9, tissue inhibitor of matrix metalloproteinase 1 (ELISA), and 27 cytokines (multiplex assay) and differential cell counts were measured in induced sputum. Airway thickness was measured by means of high-resolution computed tomographic scanning.
Results
Chronic persistent obstruction was associated with earlier age of onset, longer disease duration, more inflammatory cells in the sputum, and greater smooth muscle area (15.65% ± 2.69% [n = 10] vs 8.96% ± 1.99% [n = 14], P = .0325). No differences between groups were found for any of the biomarker molecules measured in sputum individually. However, principal component analysis revealed that the dominant variables in the chronic persistent obstruction group were IL-12, IL-13, and IFN-γ, whereas IL-9, IL-17, monocyte chemotactic protein 1, and RANTES were dominant in the other group. Airway imaging revealed no differences between groups.
Conclusion
Subjects with severe asthma with chronic persistent obstruction have increased airway smooth muscle with ongoing TH1 and TH2 inflammatory responses. Neither airway measurements on high-resolution computed tomographic scans nor sputum analysis seem able to identify such patients.
Key words: Severe asthma, remodeling, airway smooth muscle, fibrosis, reticular basement membrane, inflammation, cytokines, high-resolution computed tomographic scan, biopsy, sputum
Abbreviations used: ASM, Airway smooth muscle, ATS, American Thoracic Society, CT, Computed tomography, ECP, Eosinophil cationic protein, FeNO, Fraction of exhaled nitric oxide, HRCT, High-resolution computed tomography, MCP, Monocyte chemotactic protein, MIP, Macrophage inflammatory protein, MMP, Matrix metalloproteinase, MPO, Myeloperoxidase, RBM, Reticular basement membrane, SMA, Smooth muscle area, TIMP, Tissue inhibitor of matrix metalloproteinase, WA%, Wall area percentage
Supported by the Richard and Edith Strauss Canada Foundation, Canadian Institutes of Health Research.
Disclosure of potential conflict of interest: H. Coxson has served as a consultant/advisor board member for GlaxoSmithKline and has received research support fro GlaxoSmithKline, Spiration, and Wyeth. C. Lemière has received research support from the National Institute for Occupational Safety and Health and the Institut de Recherche Robert-Sauvé en Santé et Sécurité du Travail and has served as an advisor to GlaxoSmithKline, AstraZeneca, and Novartis. P. Ernst has received speaker's fees from or served on an advisory board for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, and Nycomed. Q. Hamid has received research support from the McGill University Health Center Strauss Foundation. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)00637-X
doi:10.1016/j.jaci.2009.03.049
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 124, Issue 1 , Pages 45-51.e4, July 2009
